$AMST
Amesite Inc. Stock $amst

$amst Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000121390024098441 Filed on November 14, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$11.25K	$63.33K
YoY Change		-82.24%	-77.4%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$798.9K	$679.9K
YoY Change		17.51%	-50.8%
% of Gross Profit
Research & Development		$139.7K	$333.4K
YoY Change		-58.12%
% of Gross Profit
Depreciation & Amortization		$118.3K	$152.4K
YoY Change		-22.37%	-18.54%
% of Gross Profit
Operating Expenses		$938.6K	$1.013M
YoY Change		-7.37%	-45.59%
Operating Profit		-$927.3K	-$950.0K
YoY Change		-2.38%	-103.08%
Interest Expense		$19.30K	$59.30K
YoY Change		-67.45%	988.07%
% of Operating Profit
Other Income/Expense, Net		$19.30K	$0.00
YoY Change			-100.0%
Pretax Income		-$908.1K	-$890.7K
YoY Change		1.95%	-43.53%
Income Tax
% Of Pretax Income
Net Earnings		-$908.0K	-$890.7K
YoY Change		1.95%	-43.53%
Net Earnings / Revenue		-8071.51%	-1406.36%
Basic Earnings Per Share		-$0.34	-$0.35
Diluted Earnings Per Share		-$0.34	-$0.35
COMMON SHARES
Basic Shares Outstanding	2.792M shares	2.792M shares	2.542M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.435M	$4.637M
YoY Change	-69.06%	-42.64%
Cash & Equivalents	$1.435M	$4.637M
Short-Term Investments
Other Short-Term Assets	$1.062M	$76.47K
YoY Change	1288.81%	-52.44%
Inventory
Prepaid Expenses
Receivables		$18.75K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$2.497M	$4.732M
YoY Change	-47.24%	-43.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$58.45K	$82.63K
YoY Change	-29.27%	-1.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$739.3K	$780.3K
YoY Change	-5.24%	-27.7%
TOTAL ASSETS
Total Short-Term Assets	$2.497M	$4.732M
Total Long-Term Assets	$739.3K	$780.3K
Total Assets	$3.236M	$5.512M
YoY Change	-41.29%	-41.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$56.01K	$78.89K
YoY Change	-29.0%	132.69%
Accrued Expenses	$762.6K	$160.1K
YoY Change	376.45%	-56.54%
Deferred Revenue	$24.38K	$24.38K
YoY Change	0.0%	-92.87%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$843.0K	$263.3K
YoY Change	220.14%	-64.6%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$843.0K	$263.3K
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$843.0K	$263.3K
YoY Change	220.13%	-64.6%
SHAREHOLDERS EQUITY
Retained Earnings	-$38.74M	-$34.32M
YoY Change	12.88%	11.24%
Common Stock	$280.00	$255.00
YoY Change	9.8%	-91.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.393M	$5.249M
YoY Change
Total Liabilities & Shareholders Equity	$3.236M	$5.512M
YoY Change	-41.29%	-41.3%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$908.0K	-$890.7K
YoY Change	1.95%	-43.53%
Depreciation, Depletion And Amortization	$118.3K	$152.4K
YoY Change	-22.37%	-18.54%
Cash From Operating Activities	-$488.3K	-$658.8K
YoY Change	-25.88%	-18.65%
INVESTING ACTIVITIES
Capital Expenditures	$148.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$148.0K	-$65.20K
YoY Change	126.99%	-41.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		$0.00
YoY Change		-100.0%
NET CHANGE
Cash From Operating Activities	-$488.3K	-$658.8K
Cash From Investing Activities	-$148.0K	-$65.20K
Cash From Financing Activities		$0.00
Net Change In Cash	-$636.3K	-$724.0K
YoY Change	-12.12%	-177.99%
FREE CASH FLOW
Cash From Operating Activities	-$488.3K	-$658.8K
Capital Expenditures	$148.0K
Free Cash Flow	-$636.3K	-$658.8K
YoY Change	-3.42%	-18.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent		usd
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2024Q3	dei	Document Type DocumentType	10-Q
CY2024Q3	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q3	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
CY2024Q3	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q3	dei	Entity File Number EntityFileNumber	001-39553
CY2024Q3	dei	Entity Registrant Name EntityRegistrantName	AMESITE INC.
CY2024Q3	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q3	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3431718
CY2024Q3	dei	Entity Address Address Line1 EntityAddressAddressLine1	607 Shelby Street
CY2024Q3	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 700 PMB 214
CY2024Q3	dei	Entity Address City Or Town EntityAddressCityOrTown	Detroit
CY2024Q3	dei	Entity Address State Or Province EntityAddressStateOrProvince	MI
CY2024Q3	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	48226
CY2024Q3	dei	City Area Code CityAreaCode	(734)
CY2024Q3	dei	Local Phone Number LocalPhoneNumber	876-8130
CY2024Q3	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001
CY2024Q3	dei	Trading Symbol TradingSymbol	AMST
CY2024Q3	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q3	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q3	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q3	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q3	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q3	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q3	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2792440	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1434753	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2071016	usd
CY2024Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	100000	usd
CY2024Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	100000	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	30060	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	962021	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	403489	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	2496774	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	2604565	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	58447	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	64784	usd
CY2024Q3	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	680889	usd
CY2024Q2	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	644828	usd
CY2024Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	739336	usd
CY2024Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	709612	usd
CY2024Q3	us-gaap	Assets Assets	3236110	usd
CY2024Q2	us-gaap	Assets Assets	3314177	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	56014	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	48907	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	688075	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	655275	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	24375	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	74539	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	94283	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	843003	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	798465	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2792440	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2792440	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2542440	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2542440	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	280	usd
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	255	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	41134373	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	40348958	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-38741546	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-37833501	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	2393107	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	2515712	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3236110	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3314177	usd
CY2024Q3	us-gaap	Revenues Revenues	11250	usd
CY2023Q3	us-gaap	Revenues Revenues	63333	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	633122	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	438262	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	139658	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	333434	usd
CY2024Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	165814	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	241627	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	938594	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	1013323	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-927344	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-949990	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	19299	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	59297	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	19299	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	59297	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-908045	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-890693	usd
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2707275	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2542440	shares
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	6084425	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-890693	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	55098	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	5248830	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	2515712	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-908045	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	720000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	65440	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	2393107	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-908045	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-890693	usd
CY2024Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	118275	usd
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	152358	usd
CY2024Q3	us-gaap	Share Based Compensation ShareBasedCompensation	65440	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	55098	usd
CY2024Q3	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	720000	usd
CY2024Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-30060	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3750	usd
CY2024Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	558532	usd
CY2023Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-30210	usd
CY2024Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7109	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	8820	usd
CY2024Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	32800	usd
CY2023Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	41400	usd
CY2024Q3	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	24375	usd
CY2023Q3	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-29583	usd
CY2024Q3	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-19745	usd
CY2023Q3	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-22639	usd
CY2024Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-488263	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-658779	usd
CY2024Q3	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	148000	usd
CY2023Q3	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	65200	usd
CY2024Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-148000	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-65200	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-636263	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-723979	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2071016	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5360661	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1434753	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4636682	usd
CY2024Q3	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 1 - Nature of Business and Liquidity</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Amesite Inc. (the “Company”) was incorporated in November 2017. Amesite is a pioneering technology company specializing in the development and marketing of B2C and B2B AI-driven solutions, including its higher ed platform that offers professional learning. Leveraging its proprietary AI infrastructure, Amesite offers cutting-edge applications that cater to both individual and professional needs. NurseMagic™, the company’s mobile healthcare app, streamlines creation of nursing notes and documentation tasks, enhances patient communication, and offers personalized guidance to nurses on patient care, medications, and handling challenging workplace situations.</span></p>
CY2024Q3	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of condensed financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2024Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	3993691	usd
CY2023Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	3618990	usd
CY2024Q3	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	148000	usd
CY2023Q3	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	65200	usd
CY2024Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	4141691	usd
CY2023Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	3684190	usd
CY2024Q2	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	3348863	usd
CY2023Q2	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	2840545	usd
CY2024Q3	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	111939	usd
CY2023Q3	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	146020	usd
CY2024Q3	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	3460802	usd
CY2023Q3	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	2986565	usd
CY2024Q3	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	680889	usd
CY2023Q3	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	697625	usd
CY2024Q3	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	111939	usd
CY2023Q3	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	146020	usd
CY2024Q3	us-gaap	Revenues Revenues	11250	usd
CY2023Q3	us-gaap	Revenues Revenues	63333	usd
CY2024Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	53948	usd
CY2024Q3	us-gaap	Gross Transaction Volume GrossTransactionVolume	35625	usd
CY2023Q3	us-gaap	Gross Transaction Volume GrossTransactionVolume	33750	usd
CY2024Q3	amst	Contract With Customers Liability Revenue Recognized ContractWithCustomersLiabilityRevenueRecognized	11250	usd
CY2023Q3	amst	Contract With Customers Liability Revenue Recognized ContractWithCustomersLiabilityRevenueRecognized	63323	usd
CY2024Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	24375	usd
CY2023Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	24375	usd
CY2024Q3	us-gaap	Deferred Income Revenue Recognized DeferredIncomeRevenueRecognized	0	usd
CY2023Q3	us-gaap	Deferred Income Revenue Recognized DeferredIncomeRevenueRecognized	26250	usd
CY2024Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2024Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	636577	shares
CY2024Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	633000	shares
CY2024Q3	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks and Uncertainties</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates in an industry subject to rapid change. The Company’s operations will be subject to significant risk and uncertainties including financial, operational, technological, and other risks associated with an early-stage company, including the potential risk of business failure.</p>
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	50052	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	235219	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	22.05
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y5M15D
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	3577	shares
CY2024Q3	amst	Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Exercise Price Additional Vesting ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAdditionalVesting	9.5
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P8Y2M23D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	238796	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	20.96
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y3M14D
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	48000	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	822524	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	250000	shares
CY2024Q3	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	720000	usd
CY2024Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	397781	shares
CY2024Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	397781	shares
CY2024Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	28400000	usd
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent		usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2024Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		usd
CY2023Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		usd
CY2023Q3	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2024Q3	dei	Amendment Flag AmendmentFlag	false
CY2024Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2024Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2025
CY2024Q3	dei	Entity Central Index Key EntityCentralIndexKey	0001807166

Files In Submission

Name	View Source	Status
0001213900-24-098441-index-headers.html	Edgar Link	pending
0001213900-24-098441-index.html	Edgar Link	pending
0001213900-24-098441.txt	Edgar Link	pending
0001213900-24-098441-xbrl.zip	Edgar Link	pending
amst-20240930.xsd	Edgar Link	pending
ea0219510-10q_amesite.htm	Edgar Link	pending
ea021951001ex31-1_amesite.htm	Edgar Link	pending
ea021951001ex31-2_amesite.htm	Edgar Link	pending
ea021951001ex32-1_amesite.htm	Edgar Link	pending
ea021951001ex32-2_amesite.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
amst-20240930_def.xml	Edgar Link	unprocessable
amst-20240930_lab.xml	Edgar Link	unprocessable
amst-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ea0219510-10q_amesite_htm.xml	Edgar Link	completed
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
amst-20240930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AMST
Amesite Inc. Stock $amst

2024 Q4 Form 10-Q Financial Statement

#000121390024098441 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMST Amesite Inc. Stock $amst

2024 Q4 Form 10-Q Financial Statement

#000121390024098441 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMST
Amesite Inc. Stock $amst